Trastuzumab Rezetecan Extends Progression-Free Survival in HER2-Positive Metastatic Colorectal Cancer

◆ TRIAL DATA

The phase III HORIZON-CRC-01 trial showed that the HER2-directed antibody-drug conjugate trastuzumab rezetecan improved median progression-free survival to 5.5 months versus 2.8 months with standard care in patients with chemotherapy-refractory, HER2-positive, RAS/RAF wild-type advanced colorectal cancer, representing a 67% reduction in the risk of disease progression or death. (The ASCO Post)